What is Abridge?
Abridge is a company that develops generative AI-powered clinical documentation tools for healthcare providers, integrating with Epic workflows. The material tracks its shift toward in-house AI models and its approach to enterprise sales without FDA clearance.
Release history
- May 2026 - Shiv Rao said about 40% of Abridge’s model outputs are generated by in-house models, with plans to increase to 60% soon by distilling and fine-tuning open-source models.
- May 2026 - Shiv Rao stated that an FDA process is not necessary to successfully sell AI tools to enterprise healthcare customers.
- May 2026 - Janie Lee or Chai Asawa said Abridge has moved customers to monthly release cycles, which is fast for health systems.
- May 2026 - Shiv Rao said Abridge does not make money selling its product, because trust is paramount in healthcare.
In the discourse
Attributed discussion of Abridge.
40% of Abridge's model outputs are currently generated by in-house models, with a target of 60% the following month after distilling and fine-tuning an open source model.
“About 40% of our model outputs inside our product are generated by in-house models.”Shiv Rao · 16 May 2026
Abridge is aggressively building in-house AI models by distilling and fine-tuning open source models to displace frontier model dependencies, a cost and control strategy worth watching in enterprise health AI.
“Next month it might be 60% because we've distilled a new open source model and fine-tuned it and gotten some feedback and, you know, we are convicted and we've just replaced a frontier model with this new in-house model.”Shiv Rao · 16 May 2026
Abridge does not require FDA approval to sell AI tools to healthcare enterprises, countering a common assumption about regulatory barriers in health AI.
“Do you have to have an FDA process to be successful selling to enterprise with AI tools? No, you don't.”Shiv Rao · 16 May 2026
Shiv Rao frames AI native companies across three historical vintages: post-Transformer paper pre-LLM, post-LLM pre-agent, and post-agent, each representing a distinct strategic starting point.
“There's like three variants of like AI native company, maybe. There's like we started 3 months after the Transformer paper. There's like in my head, there's like a post-Transformer paper pre-LLM company. There's post-LLM pre-agent company. There's post-agent company.”Shiv Rao · 16 May 2026
Abridge has moved health system customers onto monthly release cycles, a notably fast cadence for an industry that historically ships quarterly or twice a year.
“We've gotten our customers onto monthly release cycles, which is pretty fast for health systems.”Janie Lee or Chai Asawa · 14 May 2026
Abridge positions itself as a non-competitor to Epic in the healthcare AI note-taking market, a notable strategic stance given Epic's dominance in the space.
“Yeah, it's we are not competing.”Shiv Rao · 16 May 2026
Shiv Rao on Abridge's deliberate choice to forgo healthcare data revenue in service of trust.
“We don't make any money selling And we don't because trust is everything in health care.”Shiv Rao · 16 May 2026